--- title: "Press releases - Avance Clinical" canonical: "https://www.avancecro.com/press-releases/" generated: "2026-09-21T08:39:46+00:00" --- # **Press releases** [![Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge](https://www.avancecro.com/wp-content/uploads/2026/01/lumabridge-logo.jpg)](https://www.avancecro.com/press-releases/avance-clinical-strengthens-global-oncology-offering-with-acquisition-of-u-s-based-lumabridge/) 7 January 2026 ### [Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge](https://www.avancecro.com/press-releases/avance-clinical-strengthens-global-oncology-offering-with-acquisition-of-u-s-based-lumabridge/) Avance Clinical today announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials. [Read more](https://www.avancecro.com/press-releases/avance-clinical-strengthens-global-oncology-offering-with-acquisition-of-u-s-based-lumabridge/) [![Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical](https://www.avancecro.com/wp-content/uploads/2024/05/Julius-Clinical-Avance-2-600x405.jpg)](https://www.avancecro.com/press-releases/avance-clinical-expands-specialist-cns-cardiometabolic-and-rare-diseases-cro-services-in-europe-with-julius-clinical/) 28 May 2024 ### [Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical](https://www.avancecro.com/press-releases/avance-clinical-expands-specialist-cns-cardiometabolic-and-rare-diseases-cro-services-in-europe-with-julius-clinical/) - [Partnerships](https://www.avancecro.com/press-releases/?_sft_press_releases_category=partnerships) Avance Clinical has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS and rare diseases specialist CRO with extensive site relationships in the region. [Read more](https://www.avancecro.com/press-releases/avance-clinical-expands-specialist-cns-cardiometabolic-and-rare-diseases-cro-services-in-europe-with-julius-clinical/) [![Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia](https://www.avancecro.com/wp-content/uploads/2024/05/oragenics-logo-color-600x405-1-1200x810.jpg)](https://www.avancecro.com/press-releases/oragenics-partners-with-avance-clinical-for-phase-ii-concussion-trial-in-australia/) 7 May 2024 ### [Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia](https://www.avancecro.com/press-releases/oragenics-partners-with-avance-clinical-for-phase-ii-concussion-trial-in-australia/) - [Partnerships](https://www.avancecro.com/press-releases/?_sft_press_releases_category=partnerships) Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia [Read more](https://www.avancecro.com/press-releases/oragenics-partners-with-avance-clinical-for-phase-ii-concussion-trial-in-australia/) [![SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential DiseaseModifying Treatment for Type 1 Diabetes](https://www.avancecro.com/wp-content/uploads/2024/05/Sab-logo-600x405-1.jpg)](https://www.avancecro.com/press-releases/sab-biotherapeutics-announces-commencement-of-the-human-phase-1-clinical-trial-with-sab-142-a-potential-diseasemodifying-treatment-for-type-1-diabetes/) 29 November 2023 ### [SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential DiseaseModifying Treatment for Type 1 Diabetes](https://www.avancecro.com/press-releases/sab-biotherapeutics-announces-commencement-of-the-human-phase-1-clinical-trial-with-sab-142-a-potential-diseasemodifying-treatment-for-type-1-diabetes/) - [Partnerships](https://www.avancecro.com/press-releases/?_sft_press_releases_category=partnerships) SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D) through delaying the onset and/or progression of the disease, today announced that the first participants of a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study) have been dosed in Australia. [Read more](https://www.avancecro.com/press-releases/sab-biotherapeutics-announces-commencement-of-the-human-phase-1-clinical-trial-with-sab-142-a-potential-diseasemodifying-treatment-for-type-1-diabetes/) ## Proven industry **experience & expertise** ### 500+ Studies in the past 5 years ### 450+ Experienced team members ### 18k+ Participants past 5 years ### 30 Years of CRO experience [View our capabilities](https://www.avancecro.com/capabilities/our-capabilities/)